(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 18.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 109.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.12%.
Bicycle Therapeutics's revenue in 2025 is $28,339,000.On average, 17 Wall Street analysts forecast BCYC's revenue for 2025 to be $2,255,913,346, with the lowest BCYC revenue forecast at $1,672,321,237, and the highest BCYC revenue forecast at $3,124,676,875. On average, 17 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,114,680,310, with the lowest BCYC revenue forecast at $0, and the highest BCYC revenue forecast at $4,370,177,448.
In 2027, BCYC is forecast to generate $3,590,967,872 in revenue, with the lowest revenue forecast at $543,844,305 and the highest revenue forecast at $8,419,181,538.